URMC / Labs / Ritchlin Lab / Publications Publications Mease PJMerola JFTanaka YGossec LMcInnes IBRitchlin CTLandewé RBMAsahina AInk BHeinrichs ABajracharya RShende VCoarse JCoates LC Safety and Efficacy of Bimekizumab in Patients with Psoriatic Arthritis: 2-Year Results from Two Phase 3 Studies.; Rheumatology and therapy. 2024 Aug 31. Bell RDBrendel MKonnaris MAXiang JOtero MFontana MABai ZKrenitsky DMMeednu NRangel-Moreno JScheel-Toellner DCarr HNayar SMcMurray JDiCarlo EAnolik JHDonlin LTOrange DEKenney HMSchwarz EMFiler AIvashkiv LBWang F Automated multi-scale computational pathotyping (AMSCP) of inflamed synovial tissue.; Nature communications; Vol 15(1), pp. 7503. 2024 Aug 29. Kenney HMChen KLSchnur LFox JIWood RWXing LRitchlin CTRahimi HSchwarz EMAwad HA High-throughput micro-CT analysis identifies sex-dependent biomarkers of erosive arthritis in TNF-Tg mice and differential response to anti-TNF therapy.; PloS one; Vol 19(7), pp. e0305623. 2024 Jul 05. Ritchlin CTRangel-Moreno JMartino DIsett BPaine ABhattacharya SFox JMeyer EMBao RBruno TTausk Fde la Luz Garcia-Hernandez M Psoriatic arthritis subtypes are phenocopied in humanized mice.; JCI insight; Vol 9(15). 2024 Jul 02. Ritchlin CTMease PJBoehncke WHTesser JChakravarty SDRampakakis EShawi MSchiopu EMerola JFMcInnes IBDeodhar A Durable control of psoriatic arthritis with guselkumab across domains and patient characteristics: post hoc analysis of a phase 3 study.; Clinical rheumatology. 2024 Jun 07. Ogdie AMerola JFMease PJRitchlin CTScher JULafferty KPChan DChakravarty SDLangholff WWang YChoi OKrol YGottlieb AB Efficacy and safety of guselkumab in patients with active psoriatic arthritis who had inadequate efficacy and/or intolerance to one prior tumor necrosis factor inhibitor: study protocol for SOLSTICE, a phase 3B, multicenter, randomized, double-blind, placebo-controlled study.; BMC rheumatology; Vol 8(1), pp. 20. 2024 May 21. Krueger JGEyerich KKuchroo VKRitchlin CTAbreu MTElloso MMFourie AFakharzadeh SSherlock JPYang YWCua DJMcInnes IB IL-23 past, present, and future: a roadmap to advancing IL-23 science and therapy.; Frontiers in immunology; Vol 15, pp. 1331217. 2024 Apr 15. Rahman PMcInnes IBDeodhar ASchett GMease PJShawi MCua DJSherlock JPKollmeier APXu XLSheng SRitchlin CTMcGonagle D Association between enthesitis/dactylitis resolution and patient-reported outcomes in guselkumab-treated patients with psoriatic arthritis.; Clinical rheumatology. 2024 Mar 12. Coates LCLandewé RMcInnes IBMease PJRitchlin CTTanaka YAsahina ABehrens FGladman DDGossec LOrbai AMGottlieb ABWarren RBInk BBajracharya RShende VCoarse JMerola JF Bimekizumab treatment in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: 52-week safety and efficacy from the phase III BE COMPLETE study and its open-label extension BE VITAL.; RMD open; Vol 10(1). 2024 Feb 22. Chat VSEllebrecht CTKingston PBell SGondo GCordoro KMDesai SRDuffin KCFeldman SRGarg AGelfand JMGladman DGreen LJGudjonsson JHan GHawkes JEKircik LKoo JLangley RLebwohl MMichael Lewitt GLiao WMartin GOrbai AMReddy SMRichardson VRitchlin CTSchwartzman SSiegel ELVan Voorhees ASWallace EBWeinberg JMWinthrop KLYamauchi PArmstrong AW Vaccination Recommendations for Adults Receiving Biologics and Oral Therapies for Psoriasis and Psoriatic Arthritis: Delphi Consensus from the Medical Board of the National Psoriasis Foundation.; Journal of the American Academy of Dermatology. 2024 Feb 06. Furuya HNguyen CTChan TMarusina AIMerleev AAGarcia-Hernandez MLHsieh SLTsokos GCRitchlin CTTagkopoulos IMaverakis EAdamopoulos IE IL-23 induces CLEC5A+ IL-17A+ neutrophils and elicit skin inflammation associated with psoriatic arthritis.; Journal of autoimmunity; Vol 143, pp. 103167. 2024 Jan 31. Ritchlin CTCoates LCMcInnes IBMease PJMerola JFTanaka YAsahina AGossec LGottlieb ABWarren RBInk BBajracharya RShende VCoarse JLandewé RB Bimekizumab treatment in biologic DMARD-naïve patients with active psoriatic arthritis: 52-week efficacy and safety results from the phase III, randomised, placebo-controlled, active reference BE OPTIMAL study.; Annals of the rheumatic diseases. 2023 Sep 11. Kenney HMRangel-Moreno JPeng YChen KLBruno JEmbong APritchett EFox JIBecerril-Villanueva EGamboa-Domínguez AQuataert SMuthukrishnan GWood RWKorman BDAnolik JHXing LRitchlin CTSchwarz EMWu CL Multi-omics analysis identifies IgG2b class-switching with ALCAM-CD6 co-stimulation in joint-draining lymph nodes during advanced inflammatory-erosive arthritis.; Frontiers in immunology; Vol 14, pp. 1237498. 2023 Aug 25. Siebert SSweet KMRitchlin CTHsia ECKollmeier APXu XLSeridi LSong QGao SChen WMiron M Guselkumab Modulates Differentially Expressed Genes in Blood of Patients With Psoriatic Arthritis: Results from Two Phase 3, Randomized, Placebo-Controlled Trials.; ACR open rheumatology. 2023 Aug 08. Bawany FRyan Wolff JRitchlin CTTausk F Home Phototherapy Improves Access to Dermatologic Care: A Novel Stakeholder Alliance to Facilitate Its Implementation.; Clinical, cosmetic and investigational dermatology; Vol 16, pp. 1175-1180. 2023 May 02. Leung YYKavanaugh ARitchlin CT Expert Perspective: Management of the Psoriatic Arthritis Patient After Failure of One Anti-TNF inhibitor.; Arthritis & rheumatology (Hoboken, N.J.). 2023 Mar 16. McGonagle DMcInnes IBDeodhar ASchett GShawi MChakravarty SDKollmeier APXu XLSheng SXu SRitchlin CTRahman PMease PJ Guselkumab, a Selective Interleukin-23 p19 Subunit Inhibitor, Resolves Dactylitis in Patients With Active Psoriatic Arthritis: Pooled Results Through Week 52 From Two Phase 3 Studies.; ACR open rheumatology. 2023 Mar 07. Kenney HMDieudonne GYee SMaki JHWood RWSchwarz EMRitchlin CTRahimi H Near-Infrared Imaging of Indocyanine Green Identifies Novel Routes of Lymphatic Drainage from Metacarpophalangeal Joints in Healthy Human Hands.; Lymphatic research and biology. 2023 Feb 20. Ritchlin CTDeodhar ABoehncke WHSoriano ERKollmeier APXu XLZazzetti FShawi MJiang YSheng SHelliwell PS Multidomain Efficacy and Safety of Guselkumab Through 1 Year in Patients With Active Psoriatic Arthritis With and Without Prior Tumor Necrosis Factor Inhibitor Experience: Analysis of the Phase 3, Randomized, Placebo-Controlled DISCOVER-1 Study.; ACR open rheumatology. 2023 Feb 10. Kenney HMWood RWRamirez GBell RDChen KLSchnur LRahimi HKorman BDXing LRitchlin CTSchwarz EMCole CL Implementation of automated behavior metrics to evaluate voluntary wheel running effects on inflammatory-erosive arthritis and interstitial lung disease in TNF-Tg mice.; Arthritis research & therapy; Vol 25(1), pp. 17. 2023 Feb 02. Kenney HMPeng Yde Mesy Bentley KLXing LRitchlin CTSchwarz EM The Enigmas of Lymphatic Muscle Cells: Where Do They Come From, How Are They Maintained, and Can They Regenerate?; Current rheumatology reviews. 2023 Jan 27. Peng YKenney HMde Mesy Bentley KLXing LRitchlin CTSchwarz EM Distinct mast cell subpopulations within and around lymphatic vessels regulate lymph flow and progression of inflammatory-erosive arthritis in TNF-transgenic mice.; Frontiers in immunology; Vol 14, pp. 1275871. 2023 Jan 14. Ritchlin CTCoates LCMease PJvan der Heijde DSong JJiang YShawi MKollmeier APRahman P The effect of guselkumab on inhibiting radiographic progression in patients with active psoriatic arthritis: study protocol for APEX, a Phase 3b, multicenter, randomized, double-blind, placebo-controlled trial.; Trials; Vol 24(1), pp. 22. 2023 Jan 10. Kenney HMPeng YBell RDWood RWXing LRitchlin CTSchwarz EM Persistent popliteal lymphatic muscle cell coverage defects despite amelioration of arthritis and recovery of popliteal lymphatic vessel function in TNF-Tg mice following anti-TNF therapy.; Scientific reports; Vol 12(1), pp. 12751. 2022 Jul 26. Coates LCMcInnes IBMerola JFWarren RBKavanaugh AGottlieb ABGossec LAssudani DBajracharya RCoarse JInk BRitchlin CT Safety and Efficacy of Bimekizumab in Patients with Active Psoriatic Arthritis: 3-Year Results from a Phase 2b Randomized Controlled Trial and its Open-Label Extension Study.; Arthritis & rheumatology (Hoboken, N.J.). 2022 Jul 13. Orbai AMCoates LCDeodhar AHelliwell PSRitchlin CTLeibowitz EKollmeier APHsia ECXu XLSheng SJiang YLiu YHan C Meaningful Improvement in General Health Outcomes with Guselkumab Treatment for Psoriatic Arthritis: Patient-Reported Outcomes Measurement Information System-29 Results from a Phase 3 Study.; The patient. 2022 Jun 30. Coates LCRitchlin CTGossec LHelliwell PSRahman PKollmeier APXu XLShawi MKaryekar CSContré CNoël WSheng SWang YXu SMease PJ Guselkumab provides sustained domain-specific and comprehensive efficacy using composite indices in patients with active psoriatic arthritis.; Rheumatology (Oxford, England). 2022 Jun 29. Stober CMcInnes IBRaychaudhuri SMease PJPennington SRScher JUChandran VArmstrong AWde Wit MCauli AJadon DRLöve TJOgdie AO'Sullivan Dvan Mens LJJRitchlin CTFitzGerald O Proceedings of the 2021 GRAPPA-Collaborative Research Network (CRN) Meeting.; The Journal of rheumatology. 2022 Apr 01. Rangel-Moreno JGarcia-Hernandez MLOwen TBarnard JBecerril-Villanueva EKashyap TArgueta CGamboa-Dominguez ATamir SLandesman YGoldman BIRitchlin CTAnolik JH Small molecule inhibitors of nuclear export ameliorate lupus by modulating plasma cell generation and survival.; Arthritis & rheumatology (Hoboken, N.J.). 2022 Mar 25. Kenney HMWu CLLoiselle AEXing LRitchlin CTSchwarz EM Single-cell transcriptomics of popliteal lymphatic vessels and peripheral veins reveals altered lymphatic muscle and immune cell populations in the TNF-Tg arthritis model.; Arthritis research & therapy; Vol 24(1). 2022 Mar 07. Ritchlin CTMease PJBoehncke WHTesser JSchiopu EChakravarty SDKollmeier APXu XLShawi MJiang YSheng SWang YXu SMerola JFMcInnes IBDeodhar A Sustained and improved guselkumab response in patients with active psoriatic arthritis regardless of baseline demographic and disease characteristics: pooled results through week 52 of two phase III, randomised, placebo-controlled studies.; RMD open; Vol 8(1). 2022 Mar. Garcia-Hernandez MLRangel-Moreno JGarcia-Castaneda MKenney HMPaine AThullen MAnandarajah APSchwarz EMDirksen RTRitchlin CT Dendritic cell-specific transmembrane protein is required for synovitis and bone resorption in inflammatory arthritis.; Frontiers in immunology; Vol 13, pp. 1026574. 2022 Jan 07. McInnes IBAsahina ACoates LCLandewé RMerola JFRitchlin CTTanaka YGossec LGottlieb ABWarren RBInk BAssudani DBajracharya RShende VCoarse JMease PJ Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL).; Lancet (London, England). 2022 Jan 05. Merola JFLandewé RMcInnes IBMease PJRitchlin CTTanaka YAsahina ABehrens FGladman DDGossec LGottlieb ABThaçi DWarren RBInk BAssudani DBajracharya RShende VCoarse JCoates LC Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-α inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE).; Lancet (London, England). 2022 Jan 05. Gondo GCNoe MHBell SJRitchlin CT Likelihood of COVID-19 Vaccination Among Individuals Living With Psoriatic Disease: Results From a Large Real-World Survey.; Journal of psoriasis and psoriatic arthritis; Vol 7(1), pp. 17-23. 2021 Dec 10. Pournara EKormaksson MNash PRitchlin CTKirkham BWLigozio GPricop LOgdie ACoates LCSchett GMcInnes IB Clinically relevant patient clusters identified by machine learning from the clinical development programme of secukinumab in psoriatic arthritis.; RMD open; Vol 7(3). 2021 Nov. Kolbinger FDi Padova FDeodhar AHawkes JEHuppertz CKuiper TMcInnes IBRitchlin CTRosmarin DSchett GCarballido JMHäusermann PCalonder CVogel BRondeau JMBruin G Secukinumab for the treatment of psoriasis, psoriatic arthritis, and axial spondyloarthritis: Physical and pharmacological properties underlie the observed clinical efficacy and safety.; Pharmacology & therapeutics. 2021 Jun 22. Ritchlin CTArmstrong AJohnsson HMulder MLM GRAPPA Trainee Symposium 2020: A Summary of Oral and Poster Presentations.; The Journal of rheumatology. Supplement; Vol 97. 2021 Jun. Stober CJadon DRArmstrong AWChandran Vde Wit MHelliwell PSMease PJOgdie AO'Sullivan DPennington SRLöve TCauli Avan Mens LWaxman RScher JUBarton ARitchlin CTFitzGerald O Proceedings of the 2020 GRAPPA Collaborative Research Network (CRN) Meeting.; The Journal of rheumatology. Supplement; Vol 97. 2021 Jun. Ogdie ARitchlin CT Overview of the Grant Writing Workshop From the GRAPPA 2020 Annual Meeting.; The Journal of rheumatology. Supplement; Vol 97. 2021 Jun. Rahman PRitchlin CTHelliwell PSBoehncke WHMease PJGottlieb ABKafka SKollmeier APHsia ECXu XLShawi MSheng SAgarwal PZhou BRamachandran PZhuang YMcInnes IB Pooled Safety Results Through One Year of Two Phase-3 Trials of Guselkumab in Patients with Psoriatic Arthritis.; The Journal of rheumatology. 2021 May 01. McGonagle DMcInnes IBDeodhar ASchett GShawi MKafka SKaryekar CSKollmeier APHsia ECXu XLSheng SAgarwal PZhou BRitchlin CTRahman PMease PJ Resolution of Enthesitis by Guselkumab and Relationships to Disease Burden: 1-Year Results of Two Phase-3 Psoriatic Arthritis Studies.; Rheumatology (Oxford, England). 2021 Apr 06. Ogdie ARitchlin CT Overview of the Grant Writing Workshop From the GRAPPA 2020 Annual Meeting.; The Journal of rheumatology. 2021 Feb 15. Stober CJadon DRArmstrong AWChandran Vde Wit MHelliwell PSMease POgdie AO'Sullivan DPennington SRLöve TCauli Avan Mens LWaxman RScher JUBarton ARitchlin CTFitzGerald O Proceedings of the 2020 GRAPPA Collaborative Research Network (CRN) Meeting.; The Journal of rheumatology. 2021 Feb 15. Ritchlin CTHelliwell PSBoehncke WHSoriano ERHsia ECKollmeier APChakravarty SDZazzetti FSubramanian RAXu XLZuraw QCSheng SJiang YAgarwal PZhou BZhuang YShawi MKaryekar CSDeodhar A Guselkumab, an inhibitor of the IL-23p19 subunit, provides sustained improvement in signs and symptoms of active psoriatic arthritis: 1 year results of a phase III randomised study of patients who were biologic-naïve or TNFα inhibitor-experienced.; RMD open; Vol 7(1). 2021 Feb. Gelfand JMArmstrong AWBell SAnesi GLBlauvelt ACalabrese CDommasch EDFeldman SRGladman DKircik LLebwohl MLo Re VMartin GMerola JFScher JUSchwartzman STreat JRVan Voorhees ASEllebrecht CTFenner JOcon ASyed MNWeinstein EJGondo GHeydon SKoons SRitchlin CT National Psoriasis Foundation COVID-19 Task Force guidance for management of psoriatic disease during the pandemic: Version 2-Advances in psoriatic disease management, COVID-19 vaccines, and COVID-19 treatments.; Journal of the American Academy of Dermatology. 2021 Jan 07. Scallan JPBouta EMRahimi HKenney HMRitchlin CTDavis MJSchwarz EM Ex vivo Demonstration of Functional Deficiencies in Popliteal Lymphatic Vessels From TNF-Transgenic Mice With Inflammatory Arthritis.; Frontiers in physiology; Vol 12. 2021. Kenney HMBell RDMasters EAXing LRitchlin CTSchwarz EM Lineage tracing reveals evidence of a popliteal lymphatic muscle progenitor cell that is distinct from skeletal and vascular muscle progenitors.; Scientific reports; Vol 10(1). 2020 Oct 22. Ritchlin CTGiles JTOgdie AGomez-Reino JJHelliwell PYoung PWang CWu JRomero ABWoolcott JStockert L Tofacitinib in Patients With Psoriatic Arthritis and Metabolic Syndrome: A Post hoc Analysis of Phase 3 Studies.; ACR open rheumatology; Vol 2(10). 2020 Oct. Gelfand JMArmstrong AWBell SAnesi GLBlauvelt ACalabrese CDommasch EDFeldman SRGladman DKircik LLebwohl MLo Re VMartin GMerola JFScher JUSchwartzman STreat JRVan Voorhees ASEllebrecht CTFenner JOcon ASyed MNWeinstein EJSmith JGondo GHeydon SKoons SRitchlin CT National Psoriasis Foundation COVID-19 Task Force Guidance for Management of Psoriatic Disease During the Pandemic: Version 1.; Journal of the American Academy of Dermatology. 2020 Sep 04. View All Publications